Octreotide Treatment of Acromegaly

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

The experience of St Bartholomew’s Hospital in the treatment of acromegaly with octreotide is presented. When administered intravenously and subcutaneously, octreotide had a longer circulating half-life than natural somatostatin. Subcutaneous octreotide in a range of doses (50-400 µg) caused a very similar degree of growth hormone (GH) suppression, but the duration of suppression increased with size of dose. A dose of 100 µg octreotide 8-hourly provided very good suppression of GH in acromegalic patients; occasional nocturnal escapes may be a problem of inadequate dosage. Long-term octreotide treatment in 14 patients reduced GH to below 20 mU/1 and only 1 case was apparently unresponsive. No serious side effects have so far been seen. Octreotide antibodies have been detected in 1 patient unresponsive to octreotide infusion. Gallstones have been found in 6 of 14 patients.

Related collections

Author and article information

Journal

Journal ID (publisher-id): HRE

Journal ID (nlm-ta): Horm Res Paediatr

Journal ID (doi): 10.1159/issn.1663-2818

Title: Hormone Research in Paediatrics

Publisher: S. Karger AG

ISBN: 978-3-8055-5207-3

ISBN: 978-3-318-01978-0

ISSN (Print): 1663-2818

ISSN (Electronic): 1663-2826

Publication date Subscription-year: 1990

Publication date (Print): 1990

Publication date (Electronic): 02 December 2008

Volume: 33

Issue: Suppl 1

Pages: 1-6

Affiliations

Department of Endocrinology, St Bartholomew’s Hospital Medical College, London, UK

Article

Publisher ID: 181547 Other ID: Horm Res 1990;33:1–6

DOI: 10.1159/000181547

PubMed ID: 2358293

SO-VID: e9fc0727-5114-42de-b124-98343146c35a

License:

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

Octreotide Treatment of Acromegaly

Read this article at

Abstract

Related collections

Karger: Endocrinology

Author and article information

Journal

Affiliations

Article

History

Page count

Categories

Comments

Comment on this article

Similar content 333